Holen Sie sich die Stockscreener-App
18.94
0.53%
0.10
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt TNDM?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$18.84
Offen:
$19.14
24-Stunden-Volumen:
1.52M
Relative Volume:
0.97
Marktkapitalisierung:
$1.28B
Einnahmen:
$796.00M
Nettoeinkommen (Verlust:
$-136.49M
KGV:
-9.0622
EPS:
-2.09
Netto-Cashflow:
$-64.24M
1W Leistung:
-3.66%
1M Leistung:
-6.05%
6M Leistung:
+74.72%
1J Leistung:
-41.94%
1-Tages-Spanne:
$18.45
$19.26
1-Wochen-Bereich:
$18.34
$19.81
52-Wochen-Spanne:
$9.98
$35.12
Tandem Diabetes Care Inc Stock (TNDM) Company Profile
Firmenname
Tandem Diabetes Care Inc
Sektor
Branche
Telefon
858-366-6900
Adresse
12400 HIGH BLUFF DRIVE, San Diego, CA
Compare TNDM vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TNDM
Tandem Diabetes Care Inc
|
18.94 | 1.28B | 796.00M | -136.49M | -64.24M | -2.09 |
|
ABT
Abbott Laboratories
|
113.29 | 195.21B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
SYK
Stryker Corp
|
377.32 | 141.28B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
98.49 | 123.60B | 35.48B | 4.64B | 5.41B | 3.5856 |
|
BSX
Boston Scientific Corp
|
76.28 | 113.14B | 20.08B | 2.89B | 3.82B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
78.98 | 45.52B | 6.07B | 1.06B | 799.60M | 1.8527 |
Tandem Diabetes Care Inc Stock (TNDM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-27 | Fortgesetzt | TD Cowen | Buy |
| 2025-12-16 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2025-10-21 | Fortgesetzt | Stifel | Hold |
| 2025-09-08 | Eingeleitet | Oppenheimer | Outperform |
| 2025-08-12 | Hochstufung | Citigroup | Sell → Neutral |
| 2025-08-07 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2025-07-09 | Herabstufung | Citigroup | Neutral → Sell |
| 2025-06-16 | Eingeleitet | Truist | Hold |
| 2025-04-10 | Eingeleitet | Mizuho | Neutral |
| 2025-03-05 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-03-04 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-03-03 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-02-28 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2024-12-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-11-06 | Eingeleitet | Bernstein | Outperform |
| 2024-10-04 | Eingeleitet | Goldman | Neutral |
| 2024-10-02 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-08-22 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-08-08 | Eingeleitet | Canaccord Genuity | Buy |
| 2024-05-30 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-05-22 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-04-29 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-04-25 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-03-26 | Hochstufung | Stifel | Hold → Buy |
| 2023-08-04 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-05-05 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-04-24 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-03-29 | Eingeleitet | UBS | Neutral |
| 2023-01-26 | Eingeleitet | Wolfe Research | Peer Perform |
| 2022-11-15 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-08-09 | Herabstufung | Wells Fargo | Overweight → Underweight |
| 2022-03-02 | Fortgesetzt | BofA Securities | Neutral |
| 2022-01-19 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2021-07-21 | Fortgesetzt | Cowen | Outperform |
| 2021-05-25 | Eingeleitet | Barclays | Underweight |
| 2020-12-15 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-08-20 | Eingeleitet | Wells Fargo | Overweight |
| 2020-07-31 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-07-06 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-06-18 | Bestätigt | Raymond James | Outperform |
| 2020-04-24 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-03-23 | Herabstufung | Guggenheim | Buy → Neutral |
| 2020-03-05 | Eingeleitet | Citigroup | Neutral |
| 2020-02-06 | Eingeleitet | Raymond James | Outperform |
| 2020-02-04 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2019-10-18 | Eingeleitet | Guggenheim | Buy |
| 2019-10-04 | Hochstufung | UBS | Neutral → Buy |
| 2019-05-17 | Bestätigt | BofA/Merrill | Neutral |
| 2019-05-13 | Eingeleitet | SVB Leerink | Outperform |
| 2019-03-08 | Eingeleitet | BMO Capital Markets | Outperform |
| 2019-03-05 | Bestätigt | BofA/Merrill | Neutral |
| 2019-02-27 | Bestätigt | Lake Street | Buy |
| 2018-11-21 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2018-09-26 | Bestätigt | Dougherty & Company | Buy |
| 2018-09-26 | Bestätigt | Piper Jaffray | Overweight |
Alle ansehen
Tandem Diabetes Care Inc Aktie (TNDM) Neueste Nachrichten
Tandem Diabetes Care's Earnings Outlook - Benzinga
Assessing Tandem Diabetes Care (TNDM) Valuation After Recent Share Price Weakness - Yahoo Finance
Tandem Diabetes Care, Inc. (TNDM) Investor Outlook: Exploring A 37.96% Potential Upside - DirectorsTalk Interviews
Unlocking Q4 Potential of Tandem Diabetes Care (TNDM): Exploring Wall Street Estimates for Key Metrics - Yahoo Finance
Understanding Momentum Shifts in (TNDM) - Stock Traders Daily
Did t:slim X2 Legal Probe Just Shift Tandem Diabetes Care's (TNDM) Disclosure and Risk Narrative? - simplywall.st
Tandem Diabetes Care Announces Upcoming Conference PresentationsFebruary 12, 2026 - BioSpace
Tandem Diabetes Care (TNDM) to Release Earnings on Thursday - MarketBeat
Diabetes Care Devices Market to Reach USD 42.1 Billion by 2028, Growing at a 4.8% CAGR - industrytoday.co.uk
TNDM Investor News: If You Have Suffered Losses in Tandem - GlobeNewswire
Don't buy Tandem Diabetes Care until this big thing happens - MSN
Tandem Diabetes Care, Inc. (TNDM): Investor Outlook With A 38.40% Potential Upside - DirectorsTalk Interviews
Will Tandem Diabetes Care Inc. benefit from geopolitical trends2025 Key Highlights & Expert Verified Movement Alerts - mfd.ru
What’s the beta of Tandem Diabetes Care Inc. stockEarnings Summary Report & AI Enhanced Trading Signals - mfd.ru
TNDM Investor News: If You Have Suffered Losses in Tandem Diabetes Care, Inc. (NASDAQ: TNDM), ... - Bluefield Daily Telegraph
Rosen Law Firm Encourages Tandem Diabetes Care, Inc. Investors t - GuruFocus
Rosen Law Firm Encourages Tandem Diabetes Care, Inc. Investors to Inquire About Securities Class Action InvestigationTNDM - PR Newswire
TNDM Investor News: If You Have Suffered Losses in Tandem Diabetes Care, Inc. (NASDAQ: TNDM), You Are Encouraged to Contact The Rosen Law Firm About Your Rights - GlobeNewswire Inc.
Avoiding Lag: Real-Time Signals in (TNDM) Movement - Stock Traders Daily
Abbott on track with dual sensor, FDA warns on FreeStyle Libre - Modern Healthcare
Artificial Pancreas System Market is expected to reach US$ - openPR.com
Stifel Nicolaus Reaffirms Their Hold Rating on Tandem Diabetes Care (TNDM) - The Globe and Mail
Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
Breaking Down Tandem Diabetes Care: 12 Analysts Share Their Views - Benzinga
TNDM: Stifel Maintains Hold Rating, Raises PT to $20 | TNDM Stoc - GuruFocus
Stifel Nicolaus Issues Positive Forecast for Tandem Diabetes Care (NASDAQ:TNDM) Stock Price - MarketBeat
Assessing Tandem Diabetes Care (TNDM) Valuation After Recent Share Price Momentum Shift - Sahm
Y Intercept Hong Kong Ltd Purchases Shares of 56,925 Tandem Diabetes Care, Inc. $TNDM - MarketBeat
United States Diabetes Devices Market to Reach US$ 19.44 Billion - openPR.com
Commit To Buy Tandem Diabetes Care At $13, Earn 14.2% Annualized Using Options - Nasdaq
Is Tandem Diabetes Care (TNDM) Starting To Look Attractive After Prolonged Share Price Weakness? - Yahoo Finance
Investment Review: Will Tandem Diabetes Care Inc stock benefit from M AJuly 2025 Price Swings & Stepwise Trade Signal Guides - baoquankhu1.vn
Energy Moves: Is Tandem Diabetes Care Inc forming bullish engulfing patternsWeekly Stock Analysis & Real-Time Volume Trigger Notifications - baoquankhu1.vn
Can Tandem Diabetes Care Inc. generate free cash flowJuly 2025 Snapshot & Weekly Setup with High ROI Potential - mfd.ru
Why Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Could Be Worth Watching - 富途牛牛
Tandem Diabetes Care Inc (TNDM) Stock Price Down 4.17% on Jan 28 - GuruFocus
Pleasing Signs As A Number Of Insiders Buy Tandem Diabetes Care Stock - Yahoo Finance
Improved Growth Outlook and Better-Than-Expected Results Boosted Tandem Diabetes Care (TNDM) in Q4 - Insider Monkey
Rosen Law Firm Investigates Tandem Diabetes Securities Claims - Intellectia AI
TNDM Stock: TD Cowen Boosts Price Target and Reaffirms Buy Ratin - GuruFocus
Can Tandem Diabetes Care Inc stock double in the next yearInsider Selling & Weekly Setup with ROI Potential - baoquankhu1.vn
A Look At Tandem Diabetes Care (TNDM) Valuation After Legal Probe Into t:slim X2 Pump Correction - Sahm
Discipline and Rules-Based Execution in TNDM Response - Stock Traders Daily
3 Reasons to Avoid TNDM and 1 Stock to Buy Instead - Finviz
Analysts Have Conflicting Sentiments on These Healthcare Companies: Tandem Diabetes Care (TNDM), Qiagen (QGEN) and Siemens Healthineers AG (OtherSEMHF) - The Globe and Mail
TNDM INVESTOR NEWS: ROSEN, A LONGSTANDING FIRM, Encourages Tandem Diabetes Care, Inc. Investors to Inquire About Securities Class Action InvestigationTNDM - marketscreener.com
How Device Correction and Securities Probe Will Impact Tandem Diabetes Care (TNDM) Investors - Sahm
Aug Reactions: Will Tandem Diabetes Care Inc benefit from geopolitical trendsJuly 2025 Levels & Fast Gain Swing Alerts - baoquankhu1.vn
Does Tandem Diabetes Care Inc. (TD5A) stock trade below intrinsic value2025 Market Trends & Technical Pattern Recognition Alerts - bollywoodhelpline.com
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Tandem Diabetes Care, Inc. Investors to Inquire About Securities Class Action InvestigationTNDM - TMX Newsfile
Diabetes warning issued over insulin pump error - MSN
Finanzdaten der Tandem Diabetes Care Inc-Aktie (TNDM)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.13%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):